Skip to main content
. Author manuscript; available in PMC: 2008 Aug 22.
Published in final edited form as: Cytotherapy. 2008;10(4):427–435. doi: 10.1080/14653240802075476

Table 1. Cell Therapy Products.

Cell therapy products tested in this study that are routinely tested for endotoxin

  • Immature and mature dendritic cell (DC) supernatants

  • Autologous DC tumor vaccines

  • Mature DC peptides

  • HPC-M (Hematopoietic Progenitor cells-marrow-light density)

  • T-regulatory cells (umbilical cord blood [UCB]-derived)

  • MAPC (Multipotent Adult Progenitor Cells)

  • Natural Killer (NK) cells (UCB and Peripheral Blood-derived)

  • TH2 RAPAMYCIN supernatant (lymphocyte-derived)

  • TH2/TC2 supernatant (lymphocyte-derived)

  • Gene-modified CD34 (Peripheral Blood Stem Cells [PBSC] derived/pooled)

  • Adenovirus-producing cells (supernatant)

  • Vero African Green Monkey Kidney Cell Line

  • MRC-5 cells (human lung fibroblast-derived)

  • Cytotoxic T cells (lymphocyte-derived)

Cell therapy products tested in this study that are not routinely tested for endotoxin

  • Gene-transferred CD34-positive cells (PBSC-derived)

  • Ferridex labeled CD34-positive cells (PBSC-derived)

  • Ferridex control (lymphocyte-derived)

  • DC tumor vaccine/Pre-pulse (monocyte-derived)

  • DC tumor vaccine/Post-pulse (monocyte-derived)